Abstracts tagged "inflammatory myositis and myositis"

Abstract Number: 395 • 2018 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus (SLE) with Inflammatory Myositis
Nicole Bitencourt, Elizabeth (Blair) Solow and Bonnie L. Bermas, Division of Rheumatic Diseases, UT Southwestern Medical Center, Dallas, TX
Background/Purpose: The goal of this study was to identify specific clinical features of patients with SLE who have inflammatory myositis. Methods: A retrospective chart review…
Abstract Number: 2176 • 2017 ACR/ARHP Annual Meeting
Clusterin Is Upregulated in Muscle Tissue and Serum in Idiopathic Inflammatory Myopathies and Is Associated with Clinical Disease Activity
Tereza Lennerova^1,2, Lucia Vernerova¹, Martin Klein¹, Veronika Hruskova^1,3, Lucie Andres Cerezo¹, Barbora Sumova^1,2, Michal Tomcik^1,2, Sabina Oreska^1,2, Herman F Mann^1,2, Josef Zamecnik⁴, Karel Pavelka^1,2, Jiri Vencovsky^1,2 and Ladislav Senolt^1,2, ¹Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ²Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Faculty of Science, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Department of Pathology and Molecular Medicine, 2nd Medical School and University Hospital Motol, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Clusterin (also known as apolipoprotein J) is a molecular chaperone that participates in a number of biological processes, such as inflammation and apoptosis. Recent…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].